HIV protease as an inhibitor target for the treatment of AIDS. (Q40762915)

23 September 2017

1 reference

title

HIV protease as an inhibitor target for the treatment of AIDS. (English)

1 reference

23 September 2017

0 references

0 references

Darke PL

1

1 reference

PubMed ID

8204507

23 September 2017

Huff JR

series ordinal

2

1 reference

23 September 2017

1 January 1994

1 reference

23 September 2017

Advances in Pharmacology

1 reference

23 September 2017

25

1 reference

23 September 2017

399-454

1 reference

HIV-1 protease cleaves actin during acute infection of human T-lymphocytes

23 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Synthetic "interface" peptides alter dimeric assembly of the HIV 1 and 2 proteases

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

HIV-1 proteinase is required for synthesis of pro-viral DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Isolation of mutants of human immunodeficiency virus protease based on the toxicity of the enzyme in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

A novel transglutaminase-catalyzed posttranslational modification of HIV-1 aspartyl protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Analysis of subsite preferences of HIV-1 proteinase using MA/CA junction peptides substituted at the P3-P1' positions

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Use of experimental models for the study of collagen degradation by macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Synthetic non-peptide inhibitors of HIV protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Three-dimensional structure of the complex of the Rhizopus chinensis carboxyl proteinase and pepstatin at 2.5-A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Non-peptidic anti-AIDS agents: inhibition of HIV-1 proteinase by disulfonates

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Inhibition of HIV-1 proteinase by non-peptide carboxylates

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Flavones are inhibitors of HIV-1 proteinase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Stability and activity of human immunodeficiency virus protease: comparison of the natural dimer with a homologous, single-chain tethered dimer

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

X-ray studies of aspartic proteinase-statine inhibitor complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Dissociation and association of the HIV-1 protease dimer subunits: equilibria and rates.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

The HIV-1 protease as a therapeutic target for AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Specific inhibition of HIV-1 protease by boronated porphyrins

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Design and synthesis of HIV protease inhibitors. Variations of the carboxy terminus of the HIV protease inhibitor L-682,679

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

L-696,474, a novel cytochalasin as an inhibitor of HIV-1 protease. I. The producing organism and its fermentation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

HIV-1 protease inhibitors containing statine: inhibitory potency and antiviral activity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Statine based tripeptides as potent inhibitors of HIV-1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Structure and Function of Retroviral Proteases

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

PCR amplification of HIV-1 proteinase sequences directly from lab isolates allows determination of five conserved domains

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

High resolution X-ray analyses of renin inhibitor-aspartic proteinase complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Two-step binding mechanism for HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Purification and biochemical characterization of recombinant simian immunodeficiency virus protease and comparison to human immunodeficiency virus type 1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Use of protein unfolding studies to determine the conformational and dimeric stabilities of HIV-1 and SIV proteases

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Identification of a human immunodeficiency virus-1 protease cleavage site within the 66,000 Dalton subunit of reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

1 reference

7 January 2021

Different requirements for productive interaction between the active site of HIV-1 proteinase and substrates containing -hydrophobic*hydrophobic- or -aromatic*pro- cleavage sites

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Modified oligopeptides designed to interact with the HIV-1 proteinase inhibit viral replication

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Selective phosphinate transition-state analogue inhibitors of the protease of human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

HIV-1 protease: mutagenesis of asparagine 88 indicates a domain required for dimer formation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Comparative analysis of the sequences and structures of HIV-1 and HIV-2 proteases

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Partial purification and substrate analysis of bacterially expressed HIV protease by means of monoclonal antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

The role of proteolytic processing in the morphogenesis of virus particles

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Molecular characterization of gag proteins from simian immunodeficiency virus (SIVMne).

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

HIV protease: a novel chemotherapeutic target for AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

A rational approach in the search for potent inhibitors against HIV proteinase.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Penicillin derived C2-symmetric dimers as novel inhibitors of HIV-1 proteinase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Human immunodeficiency virus-1 protease. 1. Initial velocity studies and kinetic characterization of reaction intermediates by 18O isotope exchange

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Characterization of ribosomal frameshifting in HIV-1 gag-pol expression

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Progression of early steps of human immunodeficiency virus type 1 replication in the presence of an inhibitor of viral protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Conformational flexibility in the active sites of aspartyl proteinases revealed by a pepstatin fragment binding to penicillopepsin

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Structure of the aspartic protease from Rous sarcoma retrovirus refined at 2-A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Viral proteinases: weakness in strength

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Structure-based, C2 symmetric inhibitors of HIV protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Active human immunodeficiency virus protease is required for viral infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Sub-site preferences of the aspartic proteinase from the human immunodeficiency virus, HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

HTLV-III gag protein is processed in yeast cells by the virus pol-protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Kinetic assay for HIV proteinase subunit dissociation.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among retroviral enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Standardized and simplified nomenclature for proteins common to all retroviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Purification and structural characterization of the putative gag-pol protease of human immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

HIV-1 protease inhibitory activity of L-694,746, a novel metabolite of L-689,502

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

L-696,474, a novel cytochalasin as an inhibitor of HIV-1 protease. III. Biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Complete mutagenesis of the HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Substitution mutations of the highly conserved arginine 87 of HIV-1 protease result in loss of proteolytic activity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Benzocycloalkyl amines as novel C-termini for HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Substitutions at the P2' site of gag p17-p24 affect cleavage efficiency by HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Crystal structure of a retroviral protease proves relationship to aspartic protease family

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Rational design and synthesis of a novel class of active site-targeted HIV protease inhibitors containing a hydroxymethylcarbonyl isostere. Use of phenylnorstatine or allophenylnorstatine as a transition-state mimic

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Kynostatin (KNI)-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Recombinant HIV-1 reverse transcriptase: purification, primary structure, and polymerase/ribonuclease H activities

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

In vitro inhibition of HIV-1 proteinase by cerulenin

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Peptide substrates and inhibitors of the HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

An inducible transcription factor activates expression of human immunodeficiency virus in T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Chemical synthesis and enzymatic activity of a 99-residue peptide with a sequence proposed for the human immunodeficiency virus protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

L-696,474, a novel cytochalasin as an inhibitor of HIV-1 protease. II. Isolation and structure

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Effect of two novel inhibitors of the human immunodeficiency virus protease on the maturation of the HIV gag and gag-pol polyproteins

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Processing of the structural proteins of human immunodeficiency virus type 1 in the presence of monensin and cerulenin

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

The nonmyristylated Pr160gag-pol polyprotein of human immunodeficiency virus type 1 interacts with Pr55gag and is incorporated into viruslike particles

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Brominated polyacetylenic acids from the marine sponge Xestospongia muta: inhibitors of HIV protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Human immunodeficiency virus type 1 and type 2 protease monomers are functionally interchangeable in the dimeric enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

The active site of aspartic proteinases

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

A structural model for the retroviral proteases.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Hydrolysis of synthetic chromogenic substrates by HIV-1 and HIV-2 proteinases

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Didemnaketals A and B, HIV-1 protease inhibitors from the ascidian Didemnum sp

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Investigating the stereochemistry of binding to HIV-1 protease with inhibitors containing isomers of 4-amino-3-hydroxy-5-phenylpentanoic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Substrate analog inhibitors of HIV-1 protease containing phenylnorstatine as a transition state element

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Structural and evolutionary relationships between retroviral and eukaryotic aspartic proteinases

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Hydroxyethylamine analogues of the p17/p24 substrate cleavage site are tight-binding inhibitors of HIV protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Effect of hydroxyl group configuration in hydroxyethylamine dipeptide isosteres on HIV protease inhibition. Evidence for multiple binding modes

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

New hydroxyethylamine HIV protease inhibitors that suppress viral replication

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Effective blocking of HIV-1 proteinase activity by characteristic inhibitors of aspartic proteinases

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Inhibition of the aspartic proteinase from HIV-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Processing of the precursor of NF-kappa B by the HIV-1 protease during acute infection

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

In situ processing of a retroviral nucleocapsid protein by the viral proteinase.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Rational design of peptide-based HIV proteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

HIV proteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

On the size of the active site in proteases. I. Papain

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Enzymatic activity of a synthetic 99 residue protein corresponding to the putative HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

HIV-1 reproduction is inhibited by peptides derived frm the N- and C-termini of HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Potent HIV-1 protease inhibitors with antiviral activities in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Retroviral proteases: first glimpses at the anatomy of a processing machine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

The three-dimensional structure of the aspartyl protease from the HIV-1 isolate BRU

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Characterization and autoprocessing of precursor and mature forms of human immunodeficiency virus type 1 (HIV 1) protease purified from Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Intriguing structure-activity relations underlie the potent inhibition of HIV protease by norstatine-based peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

A fluorometric assay for HIV-protease activity using high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Structural evidence for gene duplication in the evolution of the acid proteases

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Crystal structure of a complex of HIV‐1 protease with a dihydroxyethylene‐containing inhibitor: Comparisons with molecular modeling

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Substrate analogue inhibition and active site titration of purified recombinant HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Proteolysis of an active site peptide of lactate dehydrogenase by human immunodeficiency virus type 1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Studies on the role of the S4 substrate binding site of HIV proteinases

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Kinetic and modeling studies of S3-S3' subsites of HIV proteinases

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Pepstatin, a new pepsin inhibitor produced by Actinomycetes

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Reduced-bond tight-binding inhibitors of HIV-1 protease. Fine tuning of the enzyme subsite specificity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Inhibition of HIV replication in cell culture by the specific aspartic protease inhibitor pepstatin A

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Molecular modeling of the HIV-1 protease and its substrate binding site

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Purification of HIV-1 wild-type protease and characterization of proteolytically inactive HIV-1 protease mutants by pepstatin A affinity chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

The effect of salt on the Michaelis Menten constant of the HIV-1 protease correlates with the Hofmeister series.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Inhibition of HIV-1 proteinase by metal ions

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Synthetic HIV-2 protease cleaves the GAG precursor of HIV-1 with the same specificity as HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

HIV-1 protease inhibitors based on hydroxyethylene dipeptide isosteres: an investigation into the role of the P1' side chain on structure-activity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

Zinc inhibition of renin and the protease from human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960438-X

7 January 2021

10.1016/S1054-3589(08)60438-X

Identifiers

DOI

0 references

PubMed ID

8204507

1 reference

PubMed ID

8204507